SNTI
Senti Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.33
−2.49%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$10.36M
MomentumView details →
1D Return
−2.49%
YTD Return
−67.87%
RSI (14)
32.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$10.36M
RSI (14)
32.2
MomentumView details →
1D Return
−2.49%
YTD Return
−67.87%
SummaryUpdated Jun 1, 2026
Senti Biosciences, Inc. (NASDAQ:SNTI) is a gene circuit company founded in 2016 and headquartered in South San Francisco, California. The company went public in May 2021 and operates in the biotechnology sector, focusing on developing advanced cell and gene therapies. Senti has positioned itself at the intersection of synthetic biology and cancer immunotherapy, utilizing engineered gene circuits to create "smart" therapeutic cells that can make complex biological decisions within the human body.
Similar companies
Latest newsMore news →
Senti Biosciences Holdings, Inc. amended its Securities Purchase Agreement to authorize the issuance and sale of $2.0 million aggregate principal of Senior Secured Convertible Notes to NSG BioInnovation Fund, L.P. in a third tranche.2d agoSenti Biosciences Holdings, Inc. issued $4.0 million aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SPV 24 pursuant to an existing securities purchase agreement dated April 27, 2026.16d ago